Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, August 11, 2022
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
[ Thu, Aug 11th 2022
] - WOPRAI
Vikram Purohit Maintained (ASND) at Buy with Decreased Target to $148 on, Aug 11th, 2022
Vikram Purohit of Morgan Stanley, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Decreased Target from $152 to $148 on, Aug 11th, 2022.
Vikram has made no other calls on ASND in the last 4 months.
There are 3 other peers that have a rating on ASND. Out of the 3 peers that are also analyzing ASND, 0 agree with Vikram's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Vikram
- David Lebowitz of "Citigroup" Maintained at Strong Buy with Decreased Target to $158 on, Thursday, May 12th, 2022
- Derek Archila of "Wells Fargo" Maintained at Buy with Decreased Target to $176 on, Thursday, May 12th, 2022
- Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $123 on, Thursday, May 12th, 2022
